全文获取类型
收费全文 | 222篇 |
免费 | 10篇 |
专业分类
儿科学 | 5篇 |
妇产科学 | 3篇 |
基础医学 | 9篇 |
口腔科学 | 6篇 |
临床医学 | 16篇 |
内科学 | 19篇 |
皮肤病学 | 2篇 |
神经病学 | 7篇 |
特种医学 | 52篇 |
外科学 | 18篇 |
预防医学 | 4篇 |
眼科学 | 2篇 |
药学 | 68篇 |
中国医学 | 3篇 |
肿瘤学 | 18篇 |
出版年
2021年 | 8篇 |
2020年 | 5篇 |
2019年 | 1篇 |
2018年 | 2篇 |
2017年 | 5篇 |
2016年 | 8篇 |
2015年 | 6篇 |
2014年 | 17篇 |
2013年 | 19篇 |
2012年 | 56篇 |
2011年 | 32篇 |
2010年 | 7篇 |
2009年 | 6篇 |
2008年 | 14篇 |
2007年 | 6篇 |
2006年 | 9篇 |
2005年 | 9篇 |
2004年 | 4篇 |
2003年 | 5篇 |
2002年 | 2篇 |
2001年 | 2篇 |
2000年 | 2篇 |
1999年 | 1篇 |
1998年 | 1篇 |
1996年 | 1篇 |
1995年 | 1篇 |
1994年 | 2篇 |
1989年 | 1篇 |
排序方式: 共有232条查询结果,搜索用时 390 毫秒
1.
Bangkim Chandra Khangembam MD Niraj Naswa MD Punit Sharma MD Chandrasekhar Bal MD Arun Malhotra MD PhD Rakesh Kumar MD PhD 《Journal of nuclear cardiology》2012,19(5):1078-1079
We present an interesting image that demonstrates utility of 68Ga-DOTANOC PET/CT for demonstrating rare metastatic sites of neuroendocrime tumor. 相似文献
2.
Patients with multiple myeloma have excellent long‐term outcomes after recovery from dialysis‐dependent acute kidney injury
下载免费PDF全文
![点击此处可从《European journal of haematology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
3.
Late port site metastasis of gall bladder carcinoma (GBC) after laparoscopic cholecystectomy is a rare finding. Rarer still is such a presentation where the GBC remained occult at histopathology. 18F-flurodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) can play an important role in this setting by supporting the diagnosis of port site metastasis, by demonstrating additional sites of metastasis, if any, and by ruling out any other primary site. We here present two such patients with late port site metastasis of occult GBC after laparoscopic cholecystectomy for cholelithiasis and discuss the role of 18F-FDG PET/CT in this setting. 相似文献
4.
Renu Singh Alexander Kozhich Chin Pan Francis Lee Pina Cardarelli Rangan Vangipuram Rama Iyer Punit Marathe 《Biopharmaceutics & drug disposition》2020,41(8-9):319-333
The growing fraction (GF) of tumor has been reported as one of the predictive markers of the efficacy of chemotherapeutics. Therefore, a semi-mechanistic model has been developed that describes tumor growth on the basis of cell cycle, allowing the incorporation of the GF of a tumor in pharmacokinetic/pharmacodynamic (PK/PD) modeling. Efficacy data of anti-glypican 3 (GPC3) antibody drug conjugate (ADC) in a hepatocellular carcinoma (HCC) patient derived xenograft (PDX) model was used for evaluation of this proposed model. Our model was able to describe the kinetics of growth inhibition of HCC PDX models following treatment with anti-GPC3 ADC remarkably well. The estimated tumurostatic concentrations were used in tandem with human PKs translated from cynomolgus monkey for prediction of the efficacious dose. The projected efficacious human dose of anti-GPC3 ADC was in the range 0.20–0.63 mg/kg for the Q3W dosing regimen, with a median dose of 0.50 mg/kg. This publication is the first step in evaluating the applicability of GF in PK/PD modeling of ADCs. The authors are hopeful that incorporation of GF will result in an improved translation of the preclinical efficacy of ADCs to clinical settings and thereby better prediction of the efficacious human dose. 相似文献
5.
Singh RK Ethayathulla AS Jabeen T Sharma S Kaur P Singh TP 《Journal of drug targeting》2005,13(2):113-119
6.
Lombardo LJ Lee FY Chen P Norris D Barrish JC Behnia K Castaneda S Cornelius LA Das J Doweyko AM Fairchild C Hunt JT Inigo I Johnston K Kamath A Kan D Klei H Marathe P Pang S Peterson R Pitt S Schieven GL Schmidt RJ Tokarski J Wen ML Wityak J Borzilleri RM 《Journal of medicinal chemistry》2004,47(27):6658-6661
A series of substituted 2-(aminopyridyl)- and 2-(aminopyrimidinyl)thiazole-5-carboxamides was identified as potent Src/Abl kinase inhibitors with excellent antiproliferative activity against hematological and solid tumor cell lines. Compound 13 was orally active in a K562 xenograft model of chronic myelogenous leukemia (CML), demonstrating complete tumor regressions and low toxicity at multiple dose levels. On the basis of its robust in vivo activity and favorable pharmacokinetic profile, 13 was selected for additional characterization for oncology indications. 相似文献
7.
8.
Yutaro Asami Tetsuya Nagata Kotaro Yoshioka Taiki Kunieda Kie Yoshida-Tanaka C. Frank Bennett Punit P. Seth Takanori Yokota 《Molecular therapy》2021,29(2):838-847
- Download : Download high-res image (148KB)
- Download : Download full-size image
9.